Glioma-associated antigen peptide-MHC complex (GAA-pMHC)

Tumor-associated antigens (TAAs) presented on peptide-MHC (pMHC) complexes represent a critical class of therapeutic targets in malignant glioma, serving as the primary interface for T-cell recognition of malignant cells [1.1.1]. These complexes are formed when intracellular or membrane proteins are degraded into short peptides and displayed on the cell surface by Major Histocompatibility Complex (MHC) molecules, most commonly HLA-A*02 in clinical applications [1.2.3, 1.5.3]. In glioma, specific antigens such as EGFRvIII, IL13Ra2, and Survivin are frequently overexpressed or mutated, creating unique pMHC signatures that distinguish tumor cells from healthy brain tissue [1.3.2, 1.3.5]. Therapeutic interventions targeting these complexes include multi-peptide vaccines like IMA950 and dendritic cell-based vaccines like ICT-107, which aim to prime the patient's immune system to mount a cytotoxic T-lymphocyte response [1.2.1, 1.3.1]. Additionally, T-cell receptor (TCR) engineered T-cell therapies (TCR-T) are under development to provide high-affinity recognition of these pMHC targets, potentially overcoming the limitations of traditional CAR-T therapies by targeting intracellularly derived antigens [1.4.1, 1.5.1]. However, the clinical efficacy of these treatments is often hindered by the blood-brain barrier, significant antigen heterogeneity, and the ability of glioma cells to downregulate MHC expression to evade immune detection [1.1.2, 1.4.2].

Other names

Tumor-associated antigens presented on peptide-MHC complexesGlioma-associated antigens (GAAs)HLA-presented glioma peptidesTumor-associated peptides (TUMAPs)Glioma immunopeptidome

Induction of antigen-specific T-cell responses (CD8+ and CD4+) and immune-mediated cytotoxicity against tumor cells presenting the target peptides on their surface.